News

Prograf is currently approved for the prevention of kidney, liver and heart transplant recipients in the US. The FDA sent Japanese company Astellas an approvable letter over concerns

POT-4 is a complement inhibitor, which shuts down the complement activation system that could lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular

The last of three phase III trials evaluating Corlux for treating the psychotic features of psychotic major depression (PMD), did not achieve statistical significance compared to placebo. However,

The trial is the fourth and final planned multi-center study in the company’s phase III development program for ferumoxytol, an intravenous iron replacement therapeutic for the treatment of

In collaboration with cancer scientists, UBC stem cell researchers found that a protein called podocalyxin – which the researchers had previously shown to be a predictor of metastatic

Benign prostatic hyperplasia (BPH) afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated

Lialda is the first and only FDA-approved once daily oral formulation of mesalamine, and is available in dosages of 2.4 g/day and 4.8 g/day, allowing patients to take

The licensed technology potentially allows for the more efficient triggering of RNA interference (RNAi) and includes the use of shRNAis either delivered as RNA compositions or encoded by

The two-year-old boy from Indiana inadvertently contracted eczema vaccinatum from his father, a US soldier who had been deployed to Iraq, when he came into contact with the